Sep 2026· Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology· Vol 18 5, pp.
e70081
· 0 citations· 109 references
Medicine
TL;DR
The molecular mechanisms by which LBNCs' architecture modulates key inflammatory regulators, such as cytokine networks and oxidative pathways, to achieve superior therapeutic control are analyzed, positioning LBNCs as a transformative paradigm for refining the precision and efficacy of modern anti-inflammatory therapy.
Abstract
Aberrant inflammatory responses are crucial indicators of the onset and progression of diverse pathologies, including metabolic syndromes, autoimmune disorders, and neuroinflammation. The intrinsic intricacy and heterogeneity of these signaling pathways require innovative therapeutic approaches that allow precise immunomodulation while alleviating systemic toxicity. Lipid-based nanocarriers (LBNCs), including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, have emerged as transformative platforms to deliver a variety of therapeutic agents. The clinical maturity of these systems, catalyzed by the global success of lipid-based RNA vaccines, has established an initial safety and scalability of this framework, which is now being transitioned toward chronic inflammatory management. This review critically evaluates the structure-function relationships of LBNCs, examining how specific physicochemical attributes dictate their interaction with inflamed tissues. We analyze the molecular mechanisms by which LBNCs' architecture modulates key inflammatory regulators, such as cytokine networks and oxidative pathways, to achieve superior therapeutic control. Furthermore, we scrutinize the strategic selection of delivery routes and their direct impact on site-specific biodistribution and patient compliance. By addressing current bottlenecks in long-term immunocompatibility and regulatory characterization, this review provides a roadmap for engineering the next generation of bio-responsive anti-inflammatory nanomedicines. Collectively, these insights position LBNCs as a transformative paradigm for refining the precision and efficacy of modern anti-inflammatory therapy. This article is categorized under: Biology-Inspired Nanomaterials > Lipid-Based Structures.
To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.
A wide range of chronic illnesses, including metabolic, autoimmune, neurodegenerative, and malignant conditions, are caused by the dysregulation of inflammation, a complex, multi-scale biological defense mechanism. Despite their clinical efficacy, current pharmacotherapies such as NSAIDs, corticosteroids, and biologics...
This review systematically summarizes the latest advances in fullerene-based nanomaterials for metabolic diseases, covering areas such as type 2 diabetes, obesity, MASLD, atherosclerosis, and diabetic complications, with particular emphasis on the molecular mechanisms underlying these effects.
The therapeutic landscape for neurodegenerative diseases (NDs), including Alzheimer’s and Parkinson’s disease, remains challenging due to their complex, multifactorial pathogenesis and the limited efficacy of conventional therapies that primarily offer symptomatic relief. The emergence of nanozymes, nanomaterials with...
Ya-Nan Wang, Jin-Tao Cheng, Tao Liu et al.· Nanomaterials· 0 citations
MXenes are a recently discovered family of two-dimensional (2D) transition metal-based nanomaterials, known for their compositional diversity, exceptional tunability, structural versatility, and surface functionality. Beyond their well-established application in energy storage, MXenes have attracted growing interest fo...
Alireza Rafieerad, L. Saleth, Sanjiv Dhingra· ACS Omega· 0 citations
Abstract Sepsis is a complex and life-threatening syndrome driven by a dysregulated host response to infection, involving persistent oxidative stress, excessive inflammation, immune paralysis, metabolic disturbance, and progressive organ dysfunction. Although substantial advances have been achieved in supportive therap...
Ye-Sen Shou, Yu-Kun Liu, Xuan Zhao et al.· International Journal of Nan...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.